- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03096977
Use of the Nine Holes Peg Test in Multiple Sclerosis: Participation of Elementary Neurological Components in the Functional Evaluation of Manual Dexterity
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brussel, Belgium, 1020
- CHU Brugmann
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients included in the NCT02805634 study
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: CHUB-TST02 patients
All patients who participated in the NCT02805634 (CHUB-TST02) study.
|
Clinical evaluation of the manual dexterity through the SARA scale.
Clinical evaluation of the prehension force using a JAMAR Dynamometer. The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort. Verbal encouragement is given during four successive tentative: the last three are averaged. Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand Test carried out using a tuned fork applied to the styloid radial process. Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration. Repeat 3 times for each hand. Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level. Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament. The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others. The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response "yes" when he perceives the contact and the response time must be less than 3 sec. Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately. The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes. To determine the discrimination threshold: Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value. Perform the test 3 times. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Scale for the assessment and rating of ataxia (SARA)
Time Frame: 1 year
|
Scale for the assessment and rating of ataxia (SARA)
|
1 year
|
|
Prehension force
Time Frame: 1 year
|
Prehension force, using a JAMAR hand dynamometer
|
1 year
|
|
Tuned fork result
Time Frame: 1 year
|
Vibratory sensibility testing
|
1 year
|
|
Sermes and Weinstein test
Time Frame: 1 year
|
Tactile pressure sensation testing
|
1 year
|
|
Weber test
Time Frame: 1 year
|
Evaluate the discrimination of 2 motionless points
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bernard Dachy, MD, CHU Brugmann
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUB-Nine Holes Peg Hands
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Scale for the assessment and rating of ataxia (SARA)
-
Prof. Dr. Matthis SynofzikRecruitingAtaxiaItaly, Australia, Germany, New Zealand, Brazil, France, Turkey (Türkiye)
-
Dr. Rebecca SchuleGerman Research Foundation; German Center for Neurodegenerative Diseases (DZNE)RecruitingSpastic AtaxiaCanada, France, Germany, Italy, Netherlands, Turkey, United Kingdom
-
University of FloridaUniversity of South Florida; National Institute of Neurological Disorders and...CompletedSpinocerebellar AtaxiaUnited States
-
Pamukkale UniversityCompletedMultiple Sclerosis | Fatigue | Functionality | DexterityTurkey
-
Centre Hospitalier Universitaire de LiegeCentre Hospitalier Régional de la Citadelle; SYSNAVRecruitingNeuromuscular Diseases | Myasthenia Gravis | Huntington Disease | Myotonic Dystrophy 1 | Hereditary Spastic Paraplegia | Ataxia, Spinocerebellar | Progressive Supranuclear Palsy (PSP) | Facio-Scapulo-Humeral Dystrophy | Obesity (Disorder) | Glycogen Storage Disease Type II Pompe Disease | Charcot Marie Tooth... and other conditionsBelgium
-
Jessa HospitalCompletedScar | Minimally Invasive Cardiac SurgeryBelgium
-
Assiut UniversityCompleted
-
Assiut UniversityNot yet recruitingBenzodiazepine-Related Disorders | Psychiatric Disorder
-
Lithuanian University of Health SciencesRecruitingSchizophrenia | Cognitive Deficit | Negative Symptoms in Schizophrenia | Depressive Symptoms Due to Primary Psychotic Disorder (Diagnosis)Lithuania
-
University Hospital Schleswig-HolsteinZealand University HospitalCompletedBreast Cancer FemaleGermany